1.27  -0.09 (-6.62%)		06-08 16:00
Open: 1.36 High: 1.365 Volume: 612,210		Pre. Close: 1.36 Low: 1.27 Market Cap: 77(M)

Short term
Mid term
Targets	6-month :	1.67	1-year :	1.82
Resists	First :	1.43	Second :	1.55
Pivot price	1.32
Supports	First :	1.22	Second :	1.01
MAs	MA(5) :	1.38	MA(20) :	1.31
	MA(100) :	1.61	MA(250) :	1.54
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	46	D(3) :	58.6
RSI	RSI(14): 45.3
52-week	High :	3.19	Low :	0.87

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MAIA ] has closed above bottom band by 30.2%. Bollinger Bands are 57.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.38 - 1.39	1.39 - 1.4
Low:	1.25 - 1.26	1.26 - 1.27
Close:	1.26 - 1.27	1.27 - 1.28

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.

Thu, 04 Jun 2026
MAIA Biotechnology Inc. (MAIA) announced that its pivotal Phase III clinical trial for non-small cell lung cancer is showing strong momentum in patient enrollment and dosing. - Bitget

Thu, 04 Jun 2026
Lung cancer trial drug saw 17.8-month survival vs 5.8 on chemo in MAIA study - Stock Titan

Thu, 04 Jun 2026
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - Yahoo Finance

Wed, 03 Jun 2026
FDA clears U.S. trial of MAIA lung cancer drug for third-line patients - Stock Titan

Wed, 03 Jun 2026
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - Yahoo Finance

Tue, 02 Jun 2026
MAIA Biotechnology Executives Increase Stock Holdings, Express Confidence in Cancer Immunotherapy Development - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.